ARISTADA Trademark

Trademark Overview


On Friday, September 30, 2016, a trademark application was filed for ARISTADA with the United States Patent and Trademark Office. The USPTO has given the ARISTADA trademark a serial number of 87189103. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Friday, June 14, 2024. This trademark is owned by Alkermes Pharma Ireland Limited. The ARISTADA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases; Pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases
aristada

General Information


Serial Number87189103
Word MarkARISTADA
Filing DateFriday, September 30, 2016
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateFriday, June 14, 2024
Registration Number5392594
Registration DateTuesday, January 30, 2018
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, February 28, 2017

Trademark Statements


Description of MarkThe mark consists of the stylized dark red wording "ARISTADA". To the right is a design comprised of a gray diamond shape. One set of double bands of varying length and width runs horizontally to each of the diamond's four sides. Each double band set is a single color - light blue, dark blue, dark red and green. All of the foregoing elements are separated by a white space, with the mark appearing on a white background.
Goods and ServicesPharmaceuticals, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases; Pharmaceutical compounds, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases
Indication of Colors claimedThe color(s) red, dark blue, light blue, green, gray and white is/are claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 5, 2016
Primary Code005
First Use Anywhere DateTuesday, June 27, 2017
First Use In Commerce DateTuesday, June 27, 2017

Trademark Owner History


Party NameAlkermes Pharma Ireland Limited
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressDublin
IE

Party NameAlkermes Pharma Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDublin
IE

Party NameAlkermes Pharma Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDublin
IE

Trademark Events


Event DateEvent Description
Tuesday, October 4, 2016NEW APPLICATION ENTERED
Wednesday, October 5, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 6, 2016NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, January 10, 2017ASSIGNED TO EXAMINER
Tuesday, January 17, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 17, 2017NON-FINAL ACTION E-MAILED
Tuesday, January 17, 2017NON-FINAL ACTION WRITTEN
Thursday, January 19, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 19, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 20, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, January 22, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 8, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 28, 2017PUBLISHED FOR OPPOSITION
Tuesday, February 28, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, March 29, 2017EXTENSION OF TIME TO OPPOSE RECEIVED
Sunday, July 9, 2017EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, August 22, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, September 11, 2017TEAS STATEMENT OF USE RECEIVED
Monday, September 11, 2017USE AMENDMENT FILED
Friday, September 22, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, September 23, 2017STATEMENT OF USE PROCESSING COMPLETE
Monday, October 2, 2017ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, October 3, 2017NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, November 28, 2017PREVIOUS ALLOWANCE WITHDRAWN-TIMELY AAU
Tuesday, November 28, 2017NON-FINAL ACTION E-MAILED
Tuesday, November 28, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 28, 2017SU - NON-FINAL ACTION - WRITTEN
Thursday, December 7, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 15, 2017ASSIGNED TO LIE
Tuesday, December 26, 2017ASSIGNED TO LIE
Thursday, December 28, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 28, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 28, 2017ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, December 29, 2017NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, January 30, 2018REGISTERED-PRINCIPAL REGISTER
Monday, January 30, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, December 11, 2023TEAS SECTION 8 & 15 RECEIVED
Friday, June 14, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, June 14, 2024REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Friday, June 14, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED